Medical Oncology

NEJM Journal Club   

Questions discussed in this category


Conversely: In a patient with N2 EGFR+ NSCLC receiving radiation, would you still consider use of osimertinib?

What was the magnitude of benefit for patients with EGFRm NSCLC by stage?  Are you still considering adjuvant osimertinib for patients with earl...

If patients do recur, do you perform these tests on the initial surgical specimen or on tissue from a fresh biopsy (or both?)

Is data available regarding the percentages of patients in each arm who underwent staging PET or the breakdown of CNS imaging modalities?

Are the rates of adjuvant chemotherapy used in ADAURA consistent with real-world practice?

What parameters do you use to decide to treat beyond progression? Is there any efficacy data from this specific study subgroup in IMbrave150?

In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?


Papers discussed in this category


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01

N Engl J Med, 2020 Sep 19

J Clin Oncol, 2020 Dec 04

N Engl J Med, 2020 May 14

Liver Cancer, 2019 Sep 18

Lancet, 1998 Jul 25

Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01